Dianthus Therapeutics vs Ionis Pharmaceuticals
Dianthus Therapeutics (DNTH), health care, and Ionis Pharmaceuticals (IONS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Dianthus Therapeutics is worth $4.9B on the stock market and Ionis Pharmaceuticals $4.5B: Dianthus Therapeutics is valued at 9% more. Dianthus Therapeutics's operating margin in its latest fiscal year was -8739% and Ionis Pharmaceuticals's -40.4%. Over the past year Dianthus Therapeutics's share price has moved +119% and Ionis Pharmaceuticals's -62.4%.
Key facts
- Dianthus Therapeutics market value
- $4.9B
- Ionis Pharmaceuticals market value
- $4.5B
- Dianthus Therapeutics revenue
- $2MFY to 2025-12-31
- Ionis Pharmaceuticals revenue
- $943.7MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Dianthus Therapeutics | Ionis Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.9Bhigher | $4.5Blower |
| Revenue | $2Mlower | $943.7Mhigher |
| Earnings | -$162.3Mhigher | -$381.4Mlower |
| Employees | 92lower | 1,485higher |
| Total assets | $530.9Mlower | $3.5Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | 2406higher | 4.8lower |
| P/B | 3.9lower | 11.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -8739%lower | -40.4%higher |
| Balance sheet | ||
| Net assets | $493.4Mhigher | $489.1Mlower |
| Total liabilities | $37.5Mlower | $3Bhigher |
| Total debt | — | $1.8B |
| Cash on hand | $51.1Mlower | $372.3Mhigher |
| Price change | ||
| Today | -2.87%higher | -3.75%lower |
| 1 year | +119%higher | -62.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Julian and Felix Baker0.4% / 0.8%
Dianthus Therapeutics only (1)
- Polen Capital team<0.1%
Ionis Pharmaceuticals only (3)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Dianthus Therapeutics / Ionis Pharmaceuticals). Who owns DNTH · Who owns IONS
More on Dianthus Therapeutics
Further comparisons
Dianthus Therapeutics against its closest peers
Ionis Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Dianthus Therapeutics or Ionis Pharmaceuticals?
By market value, Dianthus Therapeutics is the larger: $4.9B against $4.5B for Ionis Pharmaceuticals. By revenue in its latest fiscal year, Ionis Pharmaceuticals is the larger: $943.7M against $2M for Dianthus Therapeutics.
Which has the higher operating margin?
Ionis Pharmaceuticals: -40.4%, against -8739% for Dianthus Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Dianthus Therapeutics and Ionis Pharmaceuticals?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “Dianthus Therapeutics vs Ionis Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/dnth-vs-ions
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.